KEYTRUDA + LENVIMA Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as 1L Treatment for Patients With Advanced RCC May 31, 2023
Merck Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab) March 31, 2023
FAILED TRIAL: Ph 3 CONTACT-03 study of cabozantinib + atezolizumab versus cabozantinib alone in RCC patients did not meet primary endpoint of PFS March 15, 2023
Opdivo® + CABOMETYX® shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in 1L Advanced RCC February 22, 2023
Detailed Results from Ph 3 COSMIC-313 Pivotal Trial in Patients with 1L RCC announced September 13, 2022
Modi-1 Ph 1/2 trial open for recruitment in patients with TNBC, ovarian cancer, head and neck cancer, and RCC April 12, 2022
